EURopean Endeavour for Chimeric Antigen Receptor Therapies

Project Information

EURE-CART

Grant agreement ID: 733297

DOI

10.3030/733297

Project closed

EC signature date 5 December 2016

Start date 1 January 2017

End date 30 June 2021

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost

€ 5 903 146,00

EU contribution

€ 5 903 146,00

Coordinated by

AGC BIOLOGICS SPA
Italy

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Websites, patent fillings, videos etc. (7)

Launch of dedicated website
Signing-up of dedicated Twitter and LinkedIn accounts
Preparation of a project logo and flyer
A White Paper on the regulatory issues of CAR-T cells
EU Workshop on the regulatory issues of CAR-T cells
Individualised press releases

Individualised press releases. Released in Month 3 and 27.

Half-day education course at Universities

Publications

Peer reviewed articles (9)

Characterization and Functional Analysis of CD44v6.CAR T Cells Endowed with a New Low-Affinity Nerve Growth Factor Receptor-Based Spacer

Author(s): Anna Stornaiuolo, Barbara Valentinis, Camilla Sirini, Cinzia Scavullo, Claudia Asperti, Dan Zhou, Yeny Martinez De La Torre, Stefano Corna, Monica Casucci, Simona Porcellini, Catia Traversari
Published in: Human Gene Therapy, Issue 32/13-14, 2021, Page(s) 744-760, ISSN 1043-0342
Publisher: Mary Ann Liebert Inc.
DOI: 10.1089/hum.2020.216

New targets and technologies for CAR-T cells

Author(s): Fabian Freitag, Marius Maucher, Zeno Riester, Michael Hudecek
Published in: Current Opinion in Oncology, Issue 32/5, 2020, Page(s) 510-517, ISSN 1040-8746
Publisher: Lippincott Williams & Wilkins Ltd.
DOI: 10.1097/cco.0000000000000653

Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia (AML)

Author(s): Hardikkumar Jetani, Almudena Navarro-Bailón, Marius Maucher, Silke Frenz, Christina Mathilde Verbruggen, Ana Yeguas, María-Belén Vidriales, Marcos González, Judit Rial Saborido, Sabrina Kraus, Katrin Mestermann, Simone Thomas, Halvard Bonig, Maik Luu, Razieh Monjezi, Dimitrios Mougiakakos, Markus Sauer, Hermann Einsele, Michael Hudecek
Published in: Blood, 2021, ISSN 0006-4971
Publisher: American Society of Hematology
DOI: 10.1182/blood.2020009192

SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF71 normal lymphocytes

Author(s): """Tea Gogishvili, Sophia Danhof, Sabrina Prommersberger, Julian Rydzek, Martin Schreder, Christian Brede, Hermann Einsele, and Michael Hudecek"" "
Published in: Blood, Issue """Volume: 130", 2017, Page(s) 2838-2847, ISSN 0006-4971
Publisher: American Society of Hematology
DOI: 10.1182/blood-2017-04-

The EURE-CART project as a prototype model for CAR T-cell immunotherapy in Europe

Author(s): Franco Locatelli, Concetta Quintarelli
Published in: European Journal of Immunology, Issue 48/2, 2018, Page(s) 216-219, ISSN 0014-2980
Publisher: John Wiley & Sons Ltd.
DOI: 10.1002/eji.201870029

Il Progetto europeo EURE-CART: l'ISS tra i partner del nuovo approccio terapeutico e personalizzato per sconfiggere le malattie neoplastiche

Author(s): """F. Moretti, F. Capone, C. Traversari, M.C. Galli"
Published in: Notiziario Istituto Superiore Sanità, Issue 31(11), 2018, Page(s) 3-5, ISSN 1827-6296
Publisher: Istituto Superiore Sanità

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies

Author(s): Xiang Zhou, Leo Rasche, K. Martin Kortüm, Sophia Danhof, Michael Hudecek, Hermann Einsele
Published in: Frontiers in Immunology, Issue 11, 2020, ISSN 1664-3224
Publisher: International Union of Immunological Societies
DOI: 10.3389/fimmu.2020.620312

What is the future of immunotherapy in multiple myeloma?

Author(s): Leo Rasche, Michael Hudecek, Hermann Einsele
Published in: Blood, Issue 136/22, 2020, Page(s) 2491-2497, ISSN 0006-4971
Publisher: American Society of Hematology
DOI: 10.1182/blood.2019004176

Overcoming key challenges in cancer immunotherapy with engineered T cells

Author(s): Silvia Arcangeli, Katrin Mestermann, Justus Weber, Chiara Bonini, Monica Casucci, Michael Hudecek
Published in: Current Opinion in Oncology, Issue 32/5, 2020, Page(s) 398-407, ISSN 1040-8746
Publisher: Lippincott Williams & Wilkins Ltd.
DOI: 10.1097/cco.0000000000000664

Non-peer reviewed articles (1)

Antibody‐Based CAR T Cells Produced by Lentiviral Transduction

Author(s): Sabrina Prommersberger, Michael Hudecek, Thomas Nerreter
Published in: Current Protocols in Immunology, Issue 128/1, 2020, ISSN 1934-3671
Publisher: Greene Pub. Associates
DOI: 10.1002/cpim.93